10:28 AM EST - Neovasc, Inc. : Announced today that the Neovasc Reducer was featured in multiple presentations during the symposium “A Proven Evidence-based therapy when Angina Persists”, held this month at the National Congress of the Italian Society of Interventional Cardiology in Milan, Italy. Neovasc, Inc.
shares T.NVCN are trading up $0.09 at $4.91.
